ALK and non-small cell lung carcinoma: Furthermore, in a trial of ALK mutated NSCLC patients treated with nivolumab and ceritinib by Felip et al, patients experienced multiple toxicities that correlated with dosage of ceritinib resulting in an amendment of the trial to lower doses with a run in period (30).